Zolpidem Dosing Schedule
The FDA-recommended starting dose is 5 mg for women and 5-10 mg for men taken once nightly immediately before bedtime, with elderly or hepatically impaired patients starting at 5 mg regardless of sex. 1
Standard Adult Dosing
- Women should receive 5 mg as the initial dose due to 45% slower drug clearance compared to men, resulting in higher blood levels and increased risk of next-morning impairment 1
- Men should start with either 5 mg or 10 mg, with the choice based on severity of insomnia 1
- If 5 mg proves ineffective in either sex, the dose may be increased to 10 mg, though this carries higher risk of next-day driving impairment 1
- The maximum dose is 10 mg once daily—never exceed this or redose during the same night 1
Special Population Dosing
Elderly Patients (≥65 years)
- Use 5 mg once daily regardless of sex due to increased sensitivity to zolpidem's sedative effects 1
- Elderly patients experience higher rates of dizziness (3% vs 0% placebo), drowsiness (5% vs 2%), and falls, particularly at doses exceeding 10 mg 1
- In non-U.S. trials, 93% of fall reports occurred in patients ≥70 years, with 82% receiving doses >10 mg 1
Hepatic Impairment
- Mild to moderate hepatic impairment: 5 mg once daily due to reduced drug clearance 1
- Severe hepatic impairment: avoid zolpidem entirely as it may contribute to encephalopathy 1
Debilitated Patients
- Use 5 mg once daily due to heightened sensitivity to CNS effects 1
Administration Guidelines
- Take immediately before bedtime with at least 7-8 hours remaining before planned awakening 1
- Administer on an empty stomach—taking with or immediately after meals delays absorption and reduces effectiveness 2, 1
- Single dose only per night—do not readminister if awakening occurs 1
Formulation-Specific Dosing
Extended-Release Formulation
- Women: 6.25 mg 2
- Men: 6.25-12.5 mg 2
- The FDA reduced recommended starting doses from 12.5 mg to 6.25 mg due to next-day impairment concerns 3, 2
- Extended-release is more effective for sleep maintenance, reducing wake-after-sleep-onset by 25 minutes 2
Sublingual Low-Dose (Middle-of-Night Awakening)
- 3.5 mg as needed when difficulty returning to sleep after middle-of-night awakening 2
- Requires at least 4 hours remaining before planned awakening 4
Oral Spray
Concomitant CNS Depressants
- Reduce zolpidem dose when combining with other CNS depressants due to additive effects 1
- Never combine with alcohol 2
Expected Clinical Effects
- Reduces sleep onset latency by 10-15 minutes compared to placebo 2, 5
- Increases total sleep time by 23-29 minutes with immediate-release formulation 2, 5
- Effects are evident from the first night of treatment 2
- Peak plasma concentration occurs in 45-60 minutes with elimination half-life of 2.4 hours 5
Critical Safety Warnings
- Risk of complex sleep behaviors including sleep-driving, sleep-eating, and sleepwalking 2
- Next-morning impairment is dose-dependent, particularly problematic with 10 mg dose in women 1
- Avoid during pregnancy and breastfeeding; if breastfeeding, interrupt for 23 hours (5 elimination half-lives) after administration 2, 1
- Use caution in respiratory conditions including asthma, COPD, and sleep apnea 2
Duration and Discontinuation
- FDA indication is for short-term use (≤4 weeks) 6
- Long-term studies up to 6 months show maintained efficacy without tolerance development at recommended doses 6, 7
- Consider intermittent dosing (2-3 nights per week rather than nightly) to reduce tolerance risk 2
- Abrupt discontinuation may produce withdrawal symptoms—taper if used chronically 2
- Minimal rebound insomnia when discontinued after recommended use 6, 7
Common Pitfalls to Avoid
- Do not use 10 mg as starting dose in women—this is the most common dosing error given FDA's 2013 mandate 1
- Do not prescribe to patients who cannot dedicate 7-8 hours to sleep, as this dramatically increases next-day impairment risk 1
- Do not overlook hepatic function—even mild impairment requires dose reduction 1
- Do not assume elderly men can tolerate higher doses—age trumps sex for dosing decisions 1